Structure−Activity Relationship Studies Leading to the Identification of (2E)-3-[l-[(2,4-Dichlorophenyl)methyl]-5-fluoro-3-methyl-lH-indol-7-yl]-N-[(4,5-dichloro-2-thienyl)sulfonyl]-2-propenamide (DG-041), a Potent and Selective Prostanoid EP3 Receptor Antagonist, as a Novel Antiplatelet Agent That Does Not Prolong Bleeding
Journal of Medicinal Chemistry2009Vol. 53(1), pp. 18–36
Citations Over TimeTop 13% of 2009 papers
Jasbir Singh, Wayne E. Zeller, Nian Zhou, Georgeta Hategan, Rama K. Mishra, Alex Polozov, Peng Yu, Emmanuel Onua, Jun Zhang, José Luis Ramírez, G Sigthorsson, Margret Thorsteinnsdottir, Alex S. Kiselyov, David E. Zembower, Þorkell Andrésson, Mark E. Gurney
Abstract
The EP(3) receptor on the platelet mediates prostaglandin E(2) potentiation of thrombogenic coagonists including collagen and adenosine diphosphate (ADP). A pharmacophore driven approach led to the identification of diverse peri-substituted heterocycles as potent and selective EP(3) receptor antagonists. A simultaneous chemical optimization and druglike assessment of prioritized molecules converged on a lead compound 50 (DG-041) that displayed favorable in vitro and functional activities as an inhibitor of human platelet aggregation. This agent is currently in human clinical trials for the treatment of atherothrombosis.
Related Papers
- → Discovery of Nonpeptidic Small-Molecule AP-1 Inhibitors: Lead Hopping Based on a Three-Dimensional Pharmacophore Model(2005)42 cited
- → Discovery of Potent Orally Bioavailable WD Repeat Domain 5 (WDR5) Inhibitors Using a Pharmacophore-Based Optimization(2022)31 cited
- → Pocket-to-Lead: Structure-Based De Novo Design of Novel Non-peptidic HIV-1 Protease Inhibitors Using the Ligand Binding Pocket as a Template(2022)9 cited
- → Design and synthesis of inhibitors of inducible nitric oxide synthase. Discovery of a new chemical lead with potential for oral bioavailability(2003)20 cited
- → Study on Selectin Blocker. 8. Lead Discovery of a Non-Sugar Antagonist Using a 3D-Pharmacophore Model(2000)19 cited